Alligator mitazalimab-arkiv - BioStock

Alligator prepares for phase III with CD40 agonist

Alligator prepares for phase III with CD40 agonist

20 February, 2024

Søren Bregenholt CEO Alligator Bioscience

Alligator’s CEO comments on restructuring plan

16 February, 2024

AlligatorBoldVision

Alligator showcases bold drug development vision

8 December, 2023

Alligator_Strong_Q3

Strong Q3 performance for Alligator Bioscience

2 November, 2023

Alligator Biosciece presents mitazalimab data

Data backs up anti-tumour effect of Alligator’s lead asset

5 October, 2023

Alligator orphan designation EMA

Alligator Bioscience expands orphan designation to Europe

30 August, 2023

Alligator CD40 durable

Phase II results indicate durability of response for Alligator’s CD40 agonist

30 June, 2023